Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium Difficile Infection: A Randomized Trial

Overview

Journal Ann Intern Med

Specialty General Medicine

Date 2016 Aug 23

PMID 27547925

Citations 272

Authors

Colleen R Kelly

Alexander Khoruts

Christopher Staley

Michael J Sadowsky

Mortadha Abd

Mustafa Alani

Brianna Bakow

Patrizia Curran

Joyce McKenney

Allison Tisch

Steven E Reinert

Jason T Machan

Lawrence J Brandt

Affiliations

Soon will be listed here.

Abstract

Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials.

Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI.

Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494).

Setting: Two academic medical centers.

Patients: 46 patients who had 3 or more recurrences of CDI and received a full course of vancomycin for their most recent acute episode.

Intervention: Fecal microbiota transplantation with donor stool (heterologous) or patient's own stool (autologous) administered by colonoscopy.

Measurements: The primary end point was resolution of diarrhea without the need for further anti-CDI therapy during the 8-week follow-up. Safety data were compared between treatment groups via review of adverse events (AEs), serious AEs (SAEs), and new medical conditions for 6 months after FMT. Fecal microbiota analyses were performed on patients' stool before and after FMT and also on donors' stool.

Results: In the intention-to-treat analysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042). Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]). All 9 patients who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT. There were no SAEs related to FMT. Donor FMT restored gut bacterial community diversity and composition to resemble that of healthy donors.

Limitation: The study included only patients who had 3 or more recurrences and excluded those who were immunocompromised and aged 75 years or older.

Conclusion: Donor stool administered via colonoscopy seemed safe and was more efficacious than autologous FMT in preventing further CDI episodes.

Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases.

Citing Articles

Causal role of the gut microbiome in certain human diseases: a narrative review.

Prosty C, Katergi K, Papenburg J, Lawandi A, Lee T, Shi H eGastroenterology. 2025; 2(3):e100086.

PMID: 39944364 PMC: 11770457. DOI: 10.1136/egastro-2024-100086.

The Future of Microbiome Therapeutics.

Pitashny M, Kesten I, Shlon D, Ben Hur D, Bar-Yoseph H Drugs. 2025; 85(2):117-125.

PMID: 39843757 PMC: 11802617. DOI: 10.1007/s40265-024-02107-3.

Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).

Vinterberg J, Oddsdottir J, Nye M, Pinton P Infect Dis Ther. 2025; 14(2):327-355.

PMID: 39821840 PMC: 11829878. DOI: 10.1007/s40121-024-01105-y.

Phocaeicola vulgatus shapes the long-term growth dynamics and evolutionary adaptations of Clostridioides difficile.

Sulaiman J, Thompson J, Cheung P, Qian Y, Mill J, James I Cell Host Microbe. 2024; 33(1):42-58.e10.

PMID: 39730002 PMC: 11852276. DOI: 10.1016/j.chom.2024.12.001.

The Role of Gastrointestinal Dysbiosis and Fecal Transplantation in Various Neurocognitive Disorders.

Castro-Vidal Z, Mathew F, Ibrahim A, Shubhangi F, Cherian R, Choi H Cureus. 2024; 16(10):e72451.

PMID: 39600755 PMC: 11594437. DOI: 10.7759/cureus.72451.

References

Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

Agrawal M, Aroniadis O, Brandt L, Kelly C, Freeman S, Surawicz C . The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J Clin Gastroenterol. 2015; 50(5):403-7. DOI: 10.1097/MCG.0000000000000410. View

Wilcox M, Planche T, Fang F, Gilligan P . What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?. J Clin Microbiol. 2010; 48(12):4347-53. PMC: 3008464. DOI: 10.1128/JCM.02028-10. View

Gough E, Shaikh H, Manges A . Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011; 53(10):994-1002. DOI: 10.1093/cid/cir632. View

Brandt L, Aroniadis O, Mellow M, Kanatzar A, Kelly C, Park T . Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012; 107(7):1079-87. DOI: 10.1038/ajg.2012.60. View

Koo H, Van J, Zhao M, Ye X, Revell P, Jiang Z . Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014; 35(6):667-73. DOI: 10.1086/676433. View

Chang J, Antonopoulos D, Kalra A, Tonelli A, Khalife W, Schmidt T . Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008; 197(3):435-8. DOI: 10.1086/525047. View

van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal E, de Vos W . Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5):407-15. DOI: 10.1056/NEJMoa1205037. View

Shankar V, Hamilton M, Khoruts A, Kilburn A, Unno T, Paliy O . Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014; 2:13. PMC: 4030581. DOI: 10.1186/2049-2618-2-13. View

10.

Polage C, Gyorke C, Kennedy M, Leslie J, Chin D, Wang S . Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med. 2015; 175(11):1792-801. PMC: 4948649. DOI: 10.1001/jamainternmed.2015.4114. View

11.

Baxter M, Ahmad T, Colville A, Sheridan R . Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant. Clin Infect Dis. 2015; 61(1):136-7. DOI: 10.1093/cid/civ247. View

12.

McFarland L, Surawicz C, Rubin M, FEKETY R, Elmer G, Greenberg R . Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999; 20(1):43-50. DOI: 10.1086/501553. View

13.

Kassam Z, Lee C, Yuan Y, Hunt R . Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013; 108(4):500-8. DOI: 10.1038/ajg.2013.59. View

14.

McFarland L, Elmer G, Surawicz C . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7):1769-75. DOI: 10.1111/j.1572-0241.2002.05839.x. View

15.

Hamilton M, Weingarden A, Unno T, Khoruts A, Sadowsky M . High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013; 4(2):125-35. PMC: 3595072. DOI: 10.4161/gmic.23571. View

16.

Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G . Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 41(9):835-43. DOI: 10.1111/apt.13144. View

17.

Gerding D, Meyer T, Lee C, Cohen S, Murthy U, Poirier A . Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015; 313(17):1719-27. DOI: 10.1001/jama.2015.3725. View

18.

Jackson M, Olefson S, Machan J, Kelly C . A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection. J Clin Gastroenterol. 2015; 50(9):742-6. PMC: 4865457. DOI: 10.1097/MCG.0000000000000447. View

19.

Surawicz C, McFarland L, Greenberg R, Rubin M, FEKETY R, Mulligan M . The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000; 31(4):1012-7. DOI: 10.1086/318130. View

20.

Zipursky J, Sidorsky T, Freedman C, Sidorsky M, Kirkland K . Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis. 2012; 55(12):1652-8. DOI: 10.1093/cid/cis809. View